InvestorsObserver
×
News Home

Should You Add Axim Biotechnologies Inc (AXIM) Stock to Your Portfolio Friday?

Friday, October 13, 2023 12:30 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Axim Biotechnologies Inc (AXIM) Stock to Your Portfolio Friday?

The 8 rating InvestorsObserver gives to Axim Biotechnologies Inc (AXIM) stock puts it near the bottom of the Healthcare sector. In addition to scoring higher than 5 percent of stocks in the Healthcare sector, AXIM’s 8 overall rating means the stock scores better than 8 of all stocks.

Overall Score - 8
AXIM has an Overall Score of 8. Find out what this means to you and get the rest of the rankings on AXIM!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 8 would rank higher than 8 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Axim Biotechnologies Inc Stock Today?

Axim Biotechnologies Inc (AXIM) stock is unchanged -3.89% while the S&P 500 is down -0.21% as of 10:01 AM on Friday, Oct 13. AXIM is flat $0.00 from the previous closing price of $0.02 on volume of 33,140 shares. Over the past year the S&P 500 has gained 18.27% while AXIM is down -75.00%. AXIM lost -$0.05 per share the over the last 12 months. Click Here to get the full Stock Report for Axim Biotechnologies Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App